Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2

Not yet recruiting

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: Tafasitamab
Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 65

Registration Number: NCT06792825

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

Phase 1

Conditions: Chronic Lymphocytic Leukaemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions: Drug: Lenalidomide

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-07

Lead Sponsor: Vitebsk Regional Clinical Cancer Centre

Target Recruit Count: 60

Registration Number: NCT06762431

Locations: 🇧🇾
Hematology/Oncology department, Vitebsk, Select a State, Belarus

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2025-01-06

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT06760156

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Epcoritamab
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2024-12-09

Last Posted Date: 2025-03-25

Lead Sponsor: Northwestern University

Target Recruit Count: 34

Registration Number: NCT06723457

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Not Applicable

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Daratumumab

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-25

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 100

Registration Number: NCT06697483

Locations: 🇨🇳
Fuxing Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

and more 1 locations

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Phase 3

Recruiting

Conditions: Multiple Myeloma
Newly Diagnosed Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2024-11-07

Last Posted Date: 2025-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 520

Registration Number: NCT06679101

Locations: 🇨🇳
GSK Investigational Site, Kaohsiung, Taiwan

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Lenalidomide

First Posted Date: 2024-11-01

Last Posted Date: 2024-11-01

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 19

Registration Number: NCT06669143

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Ibrutinib
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Biological: Obinutuzumab
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Venetoclax

First Posted Date: 2024-10-21

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT06649812

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cilta-cel
Drug: Talquetamab
Drug: Daratumumab
Drug: Bortezomib
Drug: Teclistamab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-08-29

Last Posted Date: 2025-04-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT06577025

Locations: 🇪🇸
Hosp. Univ. 12 de Octubre, Madrid, Spain
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 9 locations

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 1

Active, not recruiting

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Newly Diagnosed

Interventions: Drug: Zanubrutinib
Drug: Lenalidomide
Drug: Obinutuzumab

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT06547944

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy